Narcolepsy secondary to anti-Ma2 encephalitis: two case reports

Courssou, J.-B. Brunet de; Testard, Pauline; Sallansonnet-Froment, M.; Bréchemier, Marie-Laure; Ricard, Damien; Psimaras, Dimitri; Ferrand, Mickaël; Maillet, T.; Depierre, Patricia; Ohlmann, C.; Capron, Jean; Arnulf, Isabelle; Gales, Ana

doi:10.5664/jcsm.10448

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Narcolepsy is prevalent in patients with anti-Ma2-associated encephalitis [13][14][15]. A patient with anti-Ma2-associated encephalitis was treated with pitolisant, a wake-promoting drug that increases brain histamine release [15].…”

Section: Discussionmentioning

confidence: 99%

“…Hypersomnia was documented during the recovery phase of anti-N-methyl-d-aspartate receptor associated encephalitis [12], although MSLTs were not conducted. Narcolepsy is prevalent in patients with anti-Ma2-associated encephalitis [13][14][15]. A patient with anti-Ma2-associated encephalitis was treated with pitolisant, a wake-promoting drug that increases brain histamine release [15].…”

Section: Discussionmentioning

confidence: 99%

“…Narcolepsy is prevalent in patients with anti‐Ma2‐associated encephalitis [13–15]. A patient with anti‐Ma2‐associated encephalitis was treated with pitolisant, a wake‐promoting drug that increases brain histamine release [15]. Pitolisant is an interesting option for alleviating hypersomnolence in patients with epilepsy (common in AE) because it does not lower the epileptic threshold (unlike methylphenidate) or interfere with other drugs (unlike modafinil).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hypersomnia in anti‐glutamic acid decarboxylase 65 (GAD65) associated neurological syndromes: A pilot study

Jeantin,

Gales,

Berzero

et al. 2023

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Background and purposeDespite their detrimental impact on the quality of life in autoimmune encephalitis, sleep disorders have not been investigated in anti‐glutamic acid decarboxylase (GAD65) associated neurological syndromes.MethodsSix consecutive adult patients diagnosed with anti‐GAD65‐associated neurological syndromes (four with limbic encephalitis and two with stiff‐person syndrome) and 12 healthy controls were enrolled. Participants underwent sleep interviews and sleep studies including night‐time video‐polysomnography, followed by five daytime multiple sleep latency tests (MSLTs, to assess propensity to fall asleep) and an 18 h bed rest polysomnography (to assess excessive sleep need).ResultsPatients reported the need for daily naps and that their cognition and quality of life were altered by sleepiness, but they had normal scores on the Epworth sleepiness scale. Compared with controls, sleep latencies during the MSLT were shorter in the patient group (median 5.8 min, interquartile range [IQR] 4.5, 6.0 vs. 17.7 min, IQR 16.3, 19.7, p = 0.001), and the arousal index was reduced (2.5/h, IQR 2.3, 3.0 vs. 22.3/h, IQR 13.8, 30.0, p = 0.002), although total sleep time was similar between groups (621 min, IQR 464, 651 vs. 542.5 min, IQR 499, 582, p = 0.51). Remarkably, all six patients had MSLT latencies ≤8 min, indicating severe sleepiness. No parasomnia or sleep‐disordered breathing was detected.ConclusionCentral hypersomnia is a relevant characteristic of anti‐GAD65‐associated neurological syndromes.

show abstract